Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
about
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsPersonalized medicine in diabetes: the role of 'omics' and biomarkersExenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.Personalizing guidelines for diabetes management: twilight or dawn of the expert?Insulin tolerance test predicts the effectiveness of insulin sensitizers in japanese type 2 diabetic patientsPredictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review.Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes.Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-AnalysisMetformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetesThe clinical utility of C-peptide measurement in the care of patients with diabetesRosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound.Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin.Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.Role of Pioglitazone with Metformin or Glimepiride on Oxidative Stress-induced Nuclear Damage and Reproductive Toxicity in Diabetic RatsAntithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial.Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve tyRosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes.
P2860
Q22241134-FA5ADA37-7351-4BA0-A4A1-5F991F685AA3Q26775259-0B4E51D8-8B78-44B3-BC4E-E8E414E8890EQ30558739-4CE8C253-AC51-49AE-86D3-86BFACD56E15Q34810165-899DAEFF-E3F2-4984-A5C8-59AF58B2535DQ35111559-D964AF69-8327-46FA-8A53-EC1616CCE1ABQ35541829-AA293CFD-BAEB-4CD0-929E-631BB91245B8Q35784092-061450F7-E9F2-4C32-A3F2-C8E07EEFC0A5Q35987436-D3420F07-46D2-43FA-B030-F149F5D93CFFQ36198965-42949B9F-9D9A-4DB6-A74E-A6B4B6F0A833Q36217673-E12B58DA-4DDA-4A56-8C4D-24475A26C3CCQ36283811-CD6DC998-55B3-4BD8-8FB4-F25FC4CD5C25Q36283822-9A6421E0-1C39-4465-80D3-46AA03FB38A6Q36428052-6C00CF60-17E1-49A3-A950-FF2A8D99BFA1Q37065234-5FB19F00-80A9-4466-989F-2221758C2E9EQ37108880-DCD1B51D-8FCE-47D6-A9A4-213F093C5353Q37566650-9F1113CF-77A9-4D70-9167-5A21111AFB97Q37718287-261CFD8E-B9EA-4AB3-ADBF-8B2B98A8E42EQ39040207-0BAF4F79-DAF5-4FB3-BAE7-93575F38084EQ39107791-8DAD52BD-DBAD-4369-A0CB-2485AE7935CCQ46495618-AF97D012-9495-46C1-A702-63C8BEF3C064Q46530085-C59EC97D-5680-457C-8F6F-BF12025276EAQ46885175-05047A13-ADEB-4690-B928-8AE0F7F8810AQ46909172-4B18E573-5E16-4B32-BAFD-75B5E9C1EAADQ46920671-A20A2C64-4BFF-44C1-9C0F-E0D235C1FD1DQ51371873-23909968-CF9F-4C78-9D81-186CF3A9FFBEQ51474253-C3B0A0FB-14F6-46B2-8DCA-FB3060DE390AQ53627172-D1DABC9D-81AA-4F35-BF44-056B69BE0C20
P2860
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Addition of rosiglitazone to m ...... patients with type 2 diabetes.
@en
Addition of rosiglitazone to m ...... patients with type 2 diabetes.
@nl
type
label
Addition of rosiglitazone to m ...... patients with type 2 diabetes.
@en
Addition of rosiglitazone to m ...... patients with type 2 diabetes.
@nl
prefLabel
Addition of rosiglitazone to m ...... patients with type 2 diabetes.
@en
Addition of rosiglitazone to m ...... patients with type 2 diabetes.
@nl
P2093
P2860
P921
P1476
Addition of rosiglitazone to m ...... patients with type 2 diabetes.
@en
P2093
P2860
P304
P356
10.1046/J.1463-1326.2003.00258.X
P577
2003-05-01T00:00:00Z